After touting positive Phase III results at the American Society of Hematology’s annual meeting, the U.S. FDA placed a clinical hold on uniQure”s hemophilia B treatment AMT-061 due to a patient developing liver cancer.
https://www.pharmalive.com/wp-content/uploads/2020/12/Hope-on-Hold-Promising-Hemophilia-B-Therapy-Paused-by-FDA-BioSpace-12-21-20.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2020-12-22 04:12:272020-12-22 12:33:29Promising Hemophilia B Therapy Paused by FDA